drugset / Trial / NCT00555451
Safety, Pharmacokinetics and Potential Activity of HE3286 in Obese Adult Subjects
RandomizedSingle-groupQuadruple-blindTreatment
Summary
The objectives of this study are to evaluate the safety, tolerance and pharmacokinetics of HE3286 when administered daily for 28 days to obese adult subjects and to assess potential activity of HE3286 to decrease insulin resistance. An open-label cohort of 6 patients with type II diabetes mellitus will be treated at 10 mg (5 mg BID).
Timeline
- Start
- 2007-10
- Primary completion
- 2009-09
- Completion
- 2009-09
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | bezisterim | Small molecule | 4 mg | Oral |
| Subject | bezisterim | Small molecule | 5 mg | Oral |
| Subject | bezisterim | Small molecule | 10 mg | Oral |
| Subject | bezisterim | Small molecule | 20 mg | Oral |
| Subject | bezisterim | Small molecule | 40 mg | Oral |
Indications
No indication recorded.